GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Femasys Inc (NAS:FEMY) » Definitions » EV-to-EBIT

Femasys (Femasys) EV-to-EBIT : -1.06 (As of Jun. 04, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Femasys EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Femasys's Enterprise Value is $15.26 Mil. Femasys's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-14.37 Mil. Therefore, Femasys's EV-to-EBIT for today is -1.06.

The historical rank and industry rank for Femasys's EV-to-EBIT or its related term are showing as below:

FEMY' s EV-to-EBIT Range Over the Past 10 Years
Min: -21.62   Med: -0.18   Max: 2.36
Current: -1.06

During the past 5 years, the highest EV-to-EBIT of Femasys was 2.36. The lowest was -21.62. And the median was -0.18.

FEMY's EV-to-EBIT is ranked worse than
100% of 452 companies
in the Medical Devices & Instruments industry
Industry Median: 19.79 vs FEMY: -1.06

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Femasys's Enterprise Value for the quarter that ended in Mar. 2024 was $23.29 Mil. Femasys's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-14.37 Mil. Femasys's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -61.71%.


Femasys EV-to-EBIT Historical Data

The historical data trend for Femasys's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Femasys EV-to-EBIT Chart

Femasys Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - -2.96 0.15 -0.43

Femasys Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.26 0.24 -3.29 -0.43 -1.62

Competitive Comparison of Femasys's EV-to-EBIT

For the Medical Instruments & Supplies subindustry, Femasys's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Femasys's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Femasys's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Femasys's EV-to-EBIT falls into.



Femasys EV-to-EBIT Calculation

Femasys's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=15.255/-14.371
=-1.06

Femasys's current Enterprise Value is $15.26 Mil.
Femasys's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Femasys  (NAS:FEMY) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Femasys's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-14.371/23.287915
=-61.71 %

Femasys's Enterprise Value for the quarter that ended in Mar. 2024 was $23.29 Mil.
Femasys's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Femasys EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Femasys's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Femasys (Femasys) Business Description

Traded in Other Exchanges
N/A
Address
3950 Johns Creek Court, Suite 100, Suwanee, GA, USA, 30024
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
Executives
Keith J Kendall director 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Alistair Milnes director C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Christine E Thomas officer: SVP, Regulatory & Clinical 2836 SW 117TH STREET, GAINESVILLE FL 32606
Dov Elefant officer: Chief Financial Officer EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Wendy Perrow director C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Edward Evantash officer: Chief Medical Officer 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
John Dyett director, 10 percent owner 11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025
Adams John Q Jr director 35 WYCK HILL LANE, WESTLAKE TX 76262
Edward R Uzialko director, 10 percent owner 4605 DUDLEY LANE, ATLANTA GA 30327
Charles Larsen director 28 SANDPIPER ROAD, TAMPA FL 33609
Kathy Lee-sepsick director, officer: Chief Executive Officer 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Daniel Scott Currie officer: Senior VP, Operations 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Kelley Hoskin Violet Alexandria officer: VP, Clinical & Medical Affairs 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Gary Thompson director 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
William Benson Witte director 11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025